再鼎医药 is a globally integrated innovative biopharmaceutical company focused on patient-centered solutions, providing therapies for cancer, autoimmune diseases, infectious diseases, and central nervous system disorders.

再鼎医药

Zai Lab | 25,300 followers on LinkedIn. Delivering innovative, transformational outcomes to patients around the world  | Zai Lab is an innovative, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing transformative products that address medical conditions with significant unmet patient needs in the areas of oncology, autoimmune disorders, infectious diseases and neurological disorders. Our goal is to leverage our capabilities and resources to reach one million patients by 2030, positively impacting human health worldwide.

Talent Acquisition Leader

Brent Eberle

Carol Brugger

Senior Vice President, Investor Relations at Zai Lab

Christine Chiou

Chief Financial Officer at Zai Lab | Strategic Finance Business Partner | Biopharmaceutical Industry

Yajing Chen, PhD

Zai Lab

This week we announced our #financial results for the third quarter of 2024, along with recent product highlights and corporate updates. Learn more: https://bit.ly/3Z0pyBM #innovation #biotech #healthcare #Q3Results #investors

#ICYMI : Data from the ongoing global Phase 1 study of our investigational DLL3-targeted antibody-drug conjugate were featured in several news outlets, including Endpoints News , FirstWord Pharma and Cancer Network . To read more about how we’re continuing to develop a potential best-in-class, next-generation #ADC , visit https://bit.ly/3UoeXhv #innovation #SCLC #lungcancer #cancernews #oncology

Today on #WorldPsoriasisDay , and every day, we stand with the global community to raise awareness and fight stigma associated with this autoimmune disorder. At Zai Lab, we are committed to advocating for better understanding and #innovative treatment options for people living with #psoriasis . To learn more about the public health impact of psoriasis, check out the World Health Organization ’s global report: https://bit.ly/3UPbQiX

Today we presented data on Zai Lab’s investigational antibody drug conjugate ( #ADC ) that demonstrates promising objective response rates and safety profile in extensive-stage small-cell lung cancer. To learn more about this important step in the development of our global #oncology pipeline, please visit: https://bit.ly/3UoeXhv #ENASymp24 #innovation #healthcare #biotech

Three years into our Trust for Life program, Zai Lab is resolute in our commitments to improving human health, creating better outcomes, and acting right now. Zai Lab's 2023 Trust for Life Report illustrates our achievements toward our commitments and establishes future goals, including by maintaining gender equity in leadership and pay, and reaching one million patients by 2030. Explore our commitment to responsible corporate sustainability: https://bit.ly/4dArCob #Healthcare #Biotech #innovation #Sustainability #ESG

#NEWS : Zai Lab will be presenting data from the Phase 1 study of our investigational antibody-drug conjugate for DLL3+ solid tumors. The oral presentation at the EORTC-NCI-AACR Symposium will discuss the potential of ZL-1310 as an innovative #ADC in the treatment of small cell lung cancer. Read more about this data and our growing internally developed global #oncology pipeline: https://bit.ly/3Uro3Kv #ENASymp24 #SCLC #oncology #innovation #cancerresearch

Congratulations to our partner Bristol Myers Squibb on yesterday's FDA approval. We join in the goal of improving outcomes for people with #schizophrenia worldwide. #mentalhealth #innovation #healthcare #biotech

We are thrilled to welcome Dr. Prista Charuworn to Zai Lab as Vice President, Immunology, Global R&D. She is responsible for leading and advancing research and development #strategy for our #immunology therapeutic area, as well as our #neuroscience and infectious disease assets. Read more about Dr. Charuworn's extensive experience and leadership in clinical development and global product strategy: https://bit.ly/4do1b4U #WelcomeToTheTeam #innovation

Last week, our Chief Medical Officer of Oncology Robert J. Brown, MD represented Zai Lab at the 2024 ESMO - European Society for Medical Oncology Congress. Read more about our internal global #oncology pipeline and data presented on anticancer immune response in advanced solid tumors: https://bit.ly/3X4lNcf #ESMO24 #innovation #healthcare #cancer #immunotherapy

#NEWS : Zai Lab is presenting data at the #EADV 2024 Congress from a preclinical trial showing the potential of a bispecific antibody for the treatment of moderate-to-severe atopic #dermatitis . This data represents advancement in the development of Zai Lab’s internal pipeline. To read more, visit https://bit.ly/47xvMM0 #EADVCongress #dermatology #healthcare #innovation #biotech

Domain Not Resolving

DNSSEC

Font Awesome

IIS 10

HSTS IncludeSubdomains PreLoad

Microsoft

PHP 7

ASP.NET 4.0

Visa

Microsoft Azure

President, Head of Global Development Oncology

Alan Sandler

Risk, Safety, Compliance

Ann Beasley

Chief Scientific Officer

Peter Huang

Founder, CEO, and Chair

Samantha Du

Member of the Board of Directors

Scott Morrison

Vice President, BioMetrics

Charlie Zhang

Senior Vice President, Head of Global Communications at Zai Lab

Danielle Halstrom

VP Program Management

Jing Cao

Senior Vice President, Clinical Research and Early Development

Karl Hsu

Senior Vice President, Global Head of Late Stage Development, Oncology

Mehrdad Mobasher

Nisa Leung

Samantha DU

Founder, CEO, & Chair

Yongjiang Hei

Chief Medical Officer, Oncology

Yingyong Xu

Vice President of Medical (Oncology)

Linda Liu

SVP, Biologics Discovery

Harald Reinhart

Chief Medical Officer, Autoimmune and Infectious Diseases

William Liang

Chief Commercial Officer & President of Greater China

China Companies With More Than 10 Employees (Top 10K)

City of Shanghai Companies With More Than 10 Employees

China Companies With More Than 100 Employees (Top 10K)

Health Care Companies With Less Than $1B in Revenue (Top 10K)

Zai Lab is an innovative biopharmaceutical company based in Shanghai focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world.

Since their founding in 2014, their experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates.

They see theirselves as the trusted partner of choice for global biopharmaceutical companies seeking to access the Chinese market. Leveraging their team’s extensive global drug development expertise, combined with their demonstrated understanding of the pharmaceutical industry, the increasingly favorable clinical and regulatory environment in China and their in-house manufacturing capabilities, they plan to continue to secure relationships with global pharmaceutical companies to further expand their pipeline and foster innovation in China.

Their team is passionate about bringing transformative new medicines to patients. Their vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing their partner’s and their own products in China and around the world. To that end, they have built manufacturing capabilities to support the clinical and commercial production of their drug candidates in China, and they expect to have further clinical production capabilities in the near future. Their team is planning to establish a specialized commercial team to support marketing of their products in China and beyond, and they are expanding their discovery efforts both internally and through collaborations with leading academic institutions.

Post-IPO Equity - Zai Lab

OrbiMed

Series C - Zai Lab

Advantech Capital

Series B - Zai Lab

Series A - Zai Lab

Qiming Venture Partners

Shanghai

China

Asia

argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China

Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

Zai Lab unveils early lung cancer data as it looks to challenge Amgen's Imdelltra

Zai Lab Announces Participation in September Investor Conferences

Zai Lab announces data published in journal 'Cell' on niraparib

Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or ...

Zai Lab exec buys stock as Augtyro, Vyvgart SC advances in China

Zai Lab Announces Participation in May and June Investor Conferences

China's CDE accepts Zai Lab sBLA for efgartigimod alfa injection for CIDP

An oral PARP inhibitor used for maintenance treatment in ovarian cancer, preventing cancer cell repair and progression.

Devices using electric fields to treat glioblastoma and malignant pleural mesothelioma by disrupting cancer cell processes.

An oral tyrosine kinase inhibitor for advanced gastrointestinal stromal tumors after prior treatments.

A tyrosine kinase inhibitor for ROS1-positive non-small cell lung cancer, addressing resistance mutations.

An antibiotic for treating community-acquired bacterial pneumonia and skin infections.

An intravenous antibiotic combination for hospital-acquired and ventilator-associated bacterial pneumonia.

news impact assignment basic	general
public peers	general	Nov 17, 2024 8:44 PM	4b9a0438
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 17, 2024 8:44 PM	60c8670a
crunchbase trigger	general	Nov 17, 2024 8:44 PM	1e66f601
crunchbase profile	general	Nov 17, 2024 9:05 PM	8b86af26
li profile	general	Nov 17, 2024 8:44 PM	7c301acf
translate crunchbase fundingrounds	general	Nov 17, 2024 9:30 PM	3dca45d3
peers	general	Nov 17, 2024 8:44 PM	b8dedc95
news basic	general	Nov 17, 2024 8:44 PM	5bfbec25
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

ZAIL

COM:ZAILABORATORY:CN

再鼎医药